Deloitte Recap LLC: biopharma business intelligence subscription tools and consulting services

Subscriber Login
- Recap IQ Series by Deloitte
- DEAL builder
- VALUATION analyzer
- DEVELOPMENT optimizer
- Recap Basic

Recap IQ Series by Deloitte™

Insight into Action

DEAL builder™:
decision support for partnering options and structure deals

VALUATION analyzer™:
decision support for asset valuation and determining effective royalty rates

DEVELOPMENT optimizer™:
decision support for identifying leading practices in clinical development

Take a Tour Right Arrow

Subscribe Now Right Arrow

Insights

Register to receive Deloitte Recap's NEW white paper

A look at how biotech companies have won a disproportionate and growing share of important oncology drug approvals.

Webinars

Insight and analysis on topics impacting the Biopharma industry

Next Webinar:
August 10, 2010

Topic:
Asset valuation front-end vs back-end - options and consequences

Signals Magazine - Insights on the latest industry developments

Recent Articles
Steady As She Goes
Biotech and specialty pharma firms raised nearly $14 billion in the first half of 2010 – and if the pace continues for the rest of the year, it could be a record-breaker.
Read more

Financial Snapshot For March 2010: Off To The Races
Recovery has been the name of the game in 2010 – and despite a number of scary events (the stock market’s dizzying plunge in early May, The debt crisis in Greece, to name two), the economy has made some real strides this year.
Read more

Allicense 2010: The Deal Of The Year
Every year about this time, biotech and big pharma business executives gather in San Francisco to attend the annual Allicense conference. The two-day confab, which will be held at the Fairmont Hotel on May 25 and 26, focuses on partnering...
Read more

A Look Back:

10 Deals that Changed Biotech
20 Compounds that Defined Biotech

Analyst's Notebook

Use the Analyst's Notebook, Recap's free online reference library, for highlights on the industry's recent key deals, trends in alliance formation, and other valuable materials.

Daily Deal for July 31, 2010

The Daily Deal is a sample, updated daily, of Recap's Deal Snapshots available in the IQ Series.

Deal Snapshots provide a visual overview of the alliance contract terms based on the deal's contract the Deloitte Recap consultants have analyzed and summarized. Access Recap's Deal Snapshots using DEAL builder - decision support for partnering options and how to structure the deal.

DEAL builder subscriber login
Find out how to subscribe

Quarterly Trends for Biotech Out-Licensing Deal Values 2004-2009

Contributed by the Deloitte Recap consultants

As collectors and analyzers of the data within our databases, the Deloitte Recap consultants are immersed in some of the best alliance data available to understand the latest industry trends.

Access Recap's Effective Royalty Rate Grapher to analyze effective royalty rates for deals by stage of development at signing using VALUATION analyzer - decision support for asset valuation, partnering decisions, and determining effective royalty rates.

VALUATION analyzer subscriber login
Find out how to subscribe

Clinical Development Analysis for July 31, 2010

The Clinical Development Analysis is a sample, updated daily, of Recap's clinical analytics available in the IQ Series.

Access Recap's unique analytics backed by detailed drug development histories using DEVELOPMENT optimizer - decision support for identifying leading practices in clinical development, including attrition and advancement rates, development and regulatory performance, and termination efficiencies. DEVELOPMENT optimizer was designed to support the technical, regulatory, and business development aspects of clinical development.

DEVELOPMENT optimizer subscriber login
Find out how to subscribe